BioSpace News Archive

EV Biologics Corp, OTC Pink:YECO, updated shareholders about a recent publication authored by its Chief Medical Officer, Dr. Jason Sanders.

Attune Medical, a pioneering medical device company with a technology platform based on temperature management using the esophageal space, has added Ty Miller to the management team as National Sales Director.

This further defines development pathways for next generation of psychedelic medicines to treat addiction.

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing STS101 nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, announced that John Kollins, its President and Chief Executive Officer, is scheduled to present in the month of November at the following conferences and invites investors to participate via webcast and in virtual one-on-one meetings.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced financial results for the three-months ended September 30, 2021.

Prothena Corporation plc (NASDAQ:PRTA), announced today that it will report its third quarter and first nine months of 2021 financial results on Thursday, November 4, 2021 after the close of the U.S. financial markets.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), announced today that 12 RECELL® System data presentations will be shared at the upcoming Southern and Northeast Regional Burn Conferences.

Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced revenue of $267.0 million for the quarter ended September 30, 2021, an increase of 9.4% compared to the quarter ended September 30, 2020.

Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, announced the appointment of Meeta Chatterjee, Ph.D., Senior Vice President of Global Business Development at Legend Biotech Corporation, as a member of its board of directors.

HeartFlow, Inc. welcomed new clinical practice guidelines from the American College of Cardiology and American Heart Association that recognized the HeartFlow FFRct Analysis with Class of Recommendation 2a, identifying it as an important tool for diagnosing coronary artery disease and guiding decision-making regarding the use of revascularization procedures such as coronary stenting or bypass surgery.